Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

<p class="MsoNormal">Featuring an interview with Dr Aaron Lisberg<span class="normaltextrun">,</span> including the following topics:</p> <ul> <li>Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) <ul> <li>Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. <em>Support Care Cancer </em>2025;33(9):756. <a href= "https://pubmed.ncbi.nlm.nih.gov/40762824/" target="_blank" rel= "noopener">Abstract</a></li> <li>Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. <em>Oncologist </em>2025;[Online ahead of print]. <a href="https://pubmed.ncbi.nlm.nih.gov/40700616/" target="_blank" rel="noopener">Abstract</a></li> <li>Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/...